Evaluation of efficacy, safety, and tolerance of a liposomal based cocktail of topical depigmenting agents for treatment of epidermal melasma - NI

SHNI Ventures LLP0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年12月19日

试验速览

暂无简介。

•1)Female and male patients, from 18-45 years of age with epidermal melasma.
•2)Subjects with mild to moderate epidermal melasma.
•3)Participants who can provide a written informed consent and photo consent form.
•4)Participants who are willing to follow up for four visits over a period of 12 weeks.
•5)Participants who are able and willing to follow all the study procedures including abstinence from usage of any OTC product related to face applications.
•6)Participants who are willing to be clinically photographed as per protocol.

•1)Patient who is not willing to participate in the study.
•2)Patients who are using other pigment reduction creams (except sunscreen and a base moisturiser).
•3)Subjects with other dermatological disorder of the face that may interfere with the study evaluation (Acne, DPN, Seborrheic melanosis)
•4)Subjects with known hypersensitivity to any of the study compunds or constituents.
•5)Subjects who are expected to be exposed to the triggering factors (excessive sun exposure, UVB photo therapy, use of OCPs).
•6)Patient who has received facial procedures like dermabrasion, chemical peels, or laser procedures within the last 1 month.
•7)Any patient as per investigator’s opinion is unfit for participation in the study.
•8)Pregnant / lactating females.

发起方

SHNI Ventures LLP